Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. has announced an Extraordinary Meeting of Shareholders scheduled for August 12, 2024, to discuss key proposals, including amendments to the company’s articles of association for preferred share creation and a restricted share unit grant for CEO Amir Reichman. Shareholders of record as of July 3, 2024, are entitled to vote, and the board recommends a vote in favor of the proposals. The meeting’s outcomes could significantly impact the company’s corporate governance and executive compensation structure.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
